Senate Rejects Tighter DTC Drug Ad Limits

Share this article:
The U.S. Senate yesterday voted against a proposal that would toughen limits on direct-to-consumer drug ads by requiring advertisers to give equal time to information about side effects and similar drugs.


In a 69-26 vote, the Senate rejected the DTC ad rule changes submitted by Sen. John Edwards, D-NC, as an amendment to the Medicare prescription drug benefit plan currently being considered by Congress.


The new rules would have required DTC drug advertisers to display information about side effects as prominently as they display a drug's benefits. Also, advertisers would have to give equal prominence to information about a drug's effectiveness compared with similar drugs.


The rules would have applied to aural, print and video information in DTC drug ads. In addition, the Food and Drug Administration would have been required to accelerate its reviews of the legality of DTC ads placed by drug companies.


Share this article:
You must be a registered member of Direct Marketing News to post a comment.

Sign up to our newsletters

Follow us on Twitter @dmnews

Latest Jobs:

More in News

Hawk Search Widens its Global Reach

Hawk Search Widens its Global Reach

Hawk Search's solution offers support for more than twice as many languages as other site search providers, according to the company.

Candidates Offer Change In The Form of Targeting

Candidates Offer Change In The Form of Targeting

A campaign for Ben Carson raised $2.8 million despite his lack of cooperation.

Target Names Retail Veteran Brian Cornell as CEO

Target Names Retail Veteran Brian Cornell as CEO

He leaves the top job at PepsiCo Foods to take the spot vacated by Greg Steinhafel in the aftermath of the data breach.